Earnings summaries and quarterly performance for AVENUE THERAPEUTICS.
Research analysts covering AVENUE THERAPEUTICS.
Recent press releases and 8-K filings for ATXI.
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
ATXI
M&A
New Projects/Investments
- On November 5, 2025, Avenue Therapeutics, Inc. (ATXI) announced the acquisition of its majority-owned subsidiary, Baergic Bio, Inc., by Axsome Therapeutics, Inc. (AXSM).
- Axsome acquired 100% of Baergic's equity interests, including global rights to BAER-101 (now AXS-17), which it plans to develop as a potential treatment for epilepsy.
- Baergic Bio shareholders are eligible to receive a $0.3 million upfront payment (less transaction expenses), potential development and regulatory milestones of up to $2.5 million for the first indication and $1.5 million for each subsequent indication, and up to $79 million in sales-based milestones, plus a tiered mid-to-high single-digit royalty on global net sales of AXS-17.
- Avenue Therapeutics expects to receive approximately 74% of all future payments and royalties from this agreement.
Nov 12, 2025, 1:00 PM
Rani Therapeutics Reports Q3 2025 Results, Announces Major Collaboration and Funding
ATXI
Earnings
New Projects/Investments
Board Change
- Rani Therapeutics announced a collaboration with Chugai Pharmaceutical Co. for multiple therapeutics, with a potential total value of up to $1.085 billion, and completed an oversubscribed private placement raising $60.3 million.
- Following the new funding, the company expects its cash runway to extend into 2028.
- For the third quarter ended September 30, 2025, Rani Therapeutics reported a net loss of $7.9 million, an improvement from a $12.7 million net loss in the same period of 2024.
- The company also appointed Abraham Bassan and Vasudev Bailey, Ph.D. to its Board of Directors.
Nov 6, 2025, 9:30 PM
Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment
ATXI
M&A
New Projects/Investments
- Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral selective GABA A \u03b12,3 receptor positive allosteric modulator, for the treatment of epilepsy.
- The acquisition was made through Axsome's purchase of a 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics, Inc..
- Axsome plans to initiate Phase 2 trial-enabling activities in 2026 for AZD7325.
- Baergic Bio shareholders will receive a $0.3 million upfront payment and are eligible for development and regulatory milestone payments totaling up to $2.5 million for the first indication and $1.5 million for each subsequent indication, plus up to $79 million in potential sales-based milestones and tiered mid-to-high single-digit royalties.
- AstraZeneca will also receive an upfront cash payment in the single digit millions, along with eligibility for development and regulatory milestone payments, sales-based milestones, and tiered mid-to-high single-digit royalties on potential global net sales of AZD7325.
Nov 6, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more